Table 1 Baseline characteristics of the patients
Characteristic | Included N = 61 | Excluded N =27 | P-value |
|---|---|---|---|
Age (Year) and median (IQR) | 37 | 39 | 0.32 |
Gender, n (%) | 0.21 | ||
Male | 49(80) | 25(93) | |
Female | 12(20) | 2(7) | |
Site of tuberculosis, n (%) | 0.93 | ||
Pulmonary | 27(44) | 13(48) | |
Disseminated | 29(48) | 12(44) | |
Extrapulmonary | 5(8) | 2(7) | |
Efavirenz dose, n (%) | 0.5 | ||
600 mg | 33(54) | 12(44) | |
800 mg | 28(46) | 15(56) | |
IRIS, n (%) | 0.1 | ||
No | 54(88.52) | 27(100) | |
Yes | 7(11.48) | 0 (0) | |
CD4, n(%) | 0.82 | ||
< 200 cells/mm3 | 41(67) | 17(63) | |
≥ 200 cells/mm3 | 20(33) | 10(37) | |
CD4, median (IQR) | 141.08(36–234) | 162.74(71–227.5) | 0.38 |
< 200 cells/mm3 | 62(31–98) | 89(34–130) | |
≥ 200 cells/mm3 | 302.6(234.8–355.2) | 288(227.2–308) | |
HIV-1 viral load (copies/ml), n (%) | 1 | ||
≤ 30,000 | 14(23) | 6(22) | |
> 30,001 | 47(77) | 21(78) |